REGULATORY

Chuikyo OKs Health Coverage for Optune Lua, CDx for Inluriyo and Elevidys

January 26, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s Central Social Insurance Medical Council (Chuikyo) on January 23 approved NHI coverage for six medical devices and three lab test products, with reimbursement listing set for March 1 and February 1, respectively. Among the devices gaining coverage is Novocure’s…

To read the full story

Guardant360 Approved in Japan as CDx for Lilly’s Inluriyo
December 24, 2025

REGULATORY

Chuikyo OKs Health Coverage for Optune Lua, CDx for Inluriyo and Elevidys
January 26, 2026
Japan to Bolster Reimbursement Incentives for Biosimilars in FY2026 Fee Revision
January 26, 2026
Japan Panel OKs AbbVie’s Aquipta, Ipsen’s Sohonos, and Novo’s IcoSema for Approval
January 26, 2026
Japan’s 1st Xolair Biosimilar Likely from Celltrion as JAN Is Assigned
January 23, 2026
DPP Vows to Scrap Off-Year Drug Price Revisions in Election Platform
January 23, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…